Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models
Cephalalgia · 2024
DOI: 10.1177/03331024231223971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2024. Verfasst von Shafaqat M Rahman und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Rochester, Department of Biomedical Engineering, Rochester, NY, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Motion Sickness. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCD NIH HHS, NIH.
Abstract (Originalsprache)
Background
Migraine and vestibular migraine are disorders associated with a heightened motion sensitivity that provoke symptoms of motion-induced nausea and motion sickness. VM affects ∼3% of adults in the USA and affects three-fold more women than men. Triptans (selective serotonin receptor agonists) relieve migraine pain but lack efficacy for vertigo. Murine models of photophobia and allodynia have used injections of calcitonin gene-related peptide (CGRP) or other migraine triggers, such as sodium nitroprusside (SNP), to induce migraine sensitivities in mice to touch and light. Yet, there is limited research on whether these triggers affect motion-induced nausea in mice, and whether migraine blockers can reduce these migraine symptoms. We hypothesized that systemic delivery of CGRP or SNP will increase motion sickness susceptibility and motion-induced nausea in mouse models, and that migraine blockers can block these changes induced by systemically delivered CGRP or SNP.
Methods
We investigated two measures of motion sickness assessment [motion sickness index (MSI) scoring and motion-induced thermoregulation] after intraperitoneal injections of either CGRP or SNP in C57BL/6J mice. The drugs olcegepant, sumatriptan and rizatriptan were used to assess the efficacy of migraine blockers.
Results
MSI measures were confounded by CGRP’s effect on gastric distress. However, analysis of tail vasodilatations as a surrogate for motion-induced nausea was robust for both migraine triggers. Only olcegepant treatment rescued tail vasodilatations.
Conclusions
These preclinical findings support the use of small molecule CGRP receptor antagonists for the treatment of motion-induced nausea of migraine, and show that triptan therapeutics are ineffective against motion-induced nausea of migraine. Trial Registration: Not Applicable
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Rochester, Department of Biomedical Engineering, Rochester, NY, USA.
- University of Rochester Medical Center, Department of Neuroscience, Del Monte Institute of Neuroscience, Rochester, NY, USA.
ORCID-Profile: Anne E Luebke
Förderung
- NIDCD NIH HHS
- NIH
Zitieren
APA
Rahman, S. M., & Luebke, A. E. (2024). Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models. Cephalalgia. https://doi.org/10.1177/03331024231223971
Vancouver
Rahman SM, Luebke AE. Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models. Cephalalgia. 2024. doi:10.1177/03331024231223971
BibTeX
@article{Rahman2024,
author = {Rahman, Shafaqat M and Luebke, Anne E},
title = {Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024231223971}
}
EUVIMED